Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec 19:2:113.
doi: 10.21037/tgh.2017.12.05. eCollection 2017.

Therapeutic drug monitoring in inflammatory bowel disease: too little too early?-comments on the American Gastroenterology Association Guideline

Heidi Y Su  1 , Mark G Ward  1 , Miles P Sparrow  1
Affiliations
Editorial

Therapeutic drug monitoring in inflammatory bowel disease: too little too early?-comments on the American Gastroenterology Association Guideline

Heidi Y Su et al. Transl Gastroenterol Hepatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

References

    1. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology 2017;153:827-34. 10.1053/j.gastro.2017.07.032 - DOI - PubMed
    1. Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology 2017;153:835-57.e6. 10.1053/j.gastro.2017.07.031 - DOI - PubMed
    1. Association AG. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Clinical Decision Support Tool. Gastroenterology 2017;153:858-9. 10.1053/j.gastro.2017.07.039 - DOI - PubMed
    1. Association AG. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Patient Guide. Gastroenterology 2017;153:860-1. 10.1053/j.gastro.2017.07.037 - DOI - PubMed
    1. Ward MG, Warner B, Unsworth N, et al. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther 2017;46:150-61. 10.1111/apt.14124 - DOI - PubMed

LinkOut - more resources